Patent 8399405 was granted and assigned to Aileron Therapeutics on March, 2013 by the United States Patent and Trademark Office.
Biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides; and methods of making and identifying such improved polypeptides.